Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinicopathologic features of non- small-cell lung cancer harboring an NTRK gene fusion
    Journal Article

    Farago, A. F.; Taylor, M. S.; Doebele, R. C.; Zhu, V. W.; Kummar, S.; Spira, A. I.; Boyle, T. A.; Haura, E. B.; Arcila, M. E.; Benayed, R.; more...
    JCO Precision Oncology (2018)

    Fulltext@MSK | Save
  • Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation
    Journal Article

    Xiao, W.; Yabe, M.; Offin, M.; Khattar, P.; Baik, J.; Daley, R. J.; Pappacena, J. J.; Roshal, M.; Zhang, Y.; Tallman, M. S.; more...
    Blood Advances (2018)

    Fulltext@MSK | Save
  • Estimation of tumor-derived mutant allele fractions in cfDNA by shallow whole genome sequencing and fragment size analysis
    Meeting Abstract

    Yang, J.; Marass, F.; Ulz, P.; Shady, M.; Cheng, M. L.; Kothari, P.; Gedvilaite, E.; Somnay, S.; Shukla, N.; Modak, S.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in treatment of patients with advanced mesothelioma
    Meeting Abstract

    Zauderer, M. G.; Hyman, D. M.; Alley, E. W.; Bendell, J. C.; Novello, S.; Bauer, T. M.; Hanauske, A. R.; Szpurka, A. M.; Kang, S.; Chatterjee, A.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations
    Meeting Abstract

    Shaw, A. T.; Martini, J. F.; Besse, B.; Bauer, T. M.; Lin, C. C.; Soo, R. A.; Riely, G. J.; Ou, S. H. I.; Clancy, J. S.; Li, S.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET mutations that induce exon14 skipping
    Meeting Abstract

    Suzawa, K.; Offin, M. D.; Kurzatkowski, C.; Liu, D.; Vojnic, M.; Smith, R. S.; Mattar, M.; Khodos, I.; de Stanchina, E.; Sabari, J. K.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) plus ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): Identification of TMB cutoff from CheckMate 568
    Meeting Abstract

    Ramalingam, S. S.; Hellmann, M. D.; Awad, M. M.; Borghaei, H.; Gainor, J.; Brahmer, J.; Spigel, D. R.; Reck, M.; O'Byrne, K. J.; Paz-Ares, L.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer
    Meeting Abstract

    Ott, P. A.; Govindan, R.; Naing, A.; Friedlander, T. W.; Margolin, K.; Lin, J. J.; Bhardwaj, N.; Hellmann, M. D.; Srinivasan, L.; Greshock, J.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Noninvasive profiling of molecular dynamics in patients receiving HER2 targeted therapies by cell-free DNA analysis
    Meeting Abstract

    Gedvilaite, E.; Stewart, C.; Yang, J.; Reichel, J.; Stephens, D.; Offin, M. D.; Jing, X.; Meng, F.; You, D.; Berger, M. F.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Nivolumab (nivo) plus ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): Initial results from CheckMate 227
    Meeting Abstract

    Hellmann, M. D.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Otterson, G.; Audigier-Valette, C.; Minenza, E.; Linardou, H.; Burgers, S.; Salman, P.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save